Quarterly ResultJun 30, 2026, 05:32 PM
Gelteq H1 Loss AUD$3.74M; Cash Drops to AUD$9,349 Amid Clinical Progress
AI Summary
Gelteq Ltd reported a loss before income tax of AUD$3.74 million for the six months ended December 31, 2025, an increase from AUD$3.30 million in the prior year. The company's cash and cash equivalents significantly decreased to AUD$9,349, and its working capital deficit widened to AUD$5.34 million. Despite these financial challenges, Gelteq made operational strides, including completing human clinical trial planning, commencing a veterinary clinical trial, and securing new debt financing of up to US$3.5 million.
Key Highlights
- Loss before income tax increased to AUD$(3,742,104) for the six months ended December 31, 2025.
- Cash and cash equivalents decreased to AUD$9,349 as of December 31, 2025.
- Working capital deficit widened to AUD$(5,338,422) by December 31, 2025.
- Net cash used in operating activities improved to AUD$(1,082,688) for H1 2025.
- Secured strategic debt financing of up to US$3.5 million in May 2026.
- Human clinical trial planning completed, expected to commence July 1, 2026.
- Veterinary clinical trial for antiparasitic drug candidate commenced.
- Corporate and administrative expenses rose to AUD$3,534,622 for H1 2025.
Price Impact
More from GELS